Introduction: Among plant viruses, the Cowpea Mosaic Virus (CPMV), of the genus Comovirus, stands out for being studied in an in situ antitumor vaccination modality, in which pattern recognition receptors are activated and lead to a cellular immune response that is effective against various tumors, while another Comovirus, the Cowpea Severe Mosaic Virus (CPSMV), remains little studied. In this context, it is feasible to produce anti-CPSMV antibodies by immunizing birds producing IgY immunoglobulin, an antibody with a high concentration in egg yolk, chemically stable, low cost, non-invasive for the animal and which does not induce human complement activation, showing high biotherapeutic and diagnostic potential. Objectives: To evaluate the immune response induced by CPSMV in laying hens and to obtain IgY antibodies to use as research input. Methods: Opinion number (CEUA-UFPA): 1326191222. The CPSMV was purified from Vigna unguiculata leaves, characterized by polyacrylamide gel (SDS-PAGE) and UV-Vis spectrometry. Two hens were given three doses of immunizations containing 50 µg of CPSMV with montanide adjuvant intramuscularly, with an interval of two and one week, respectively, between the second and third dose. Subsequently, the yolks were purified to obtain the IgY antibody by precipitation with ammonium sulfate. To examine the titration of antibodies at different dilutions, an Enzyme-Linked Immunosorbent Assay (ELISA) analysis was performed. Results: The virus was immunogenic, since it was possible to observe the presence of anti-CPSMV IgY antibodies in the egg yolks of immunized chickens. The IgY anti-CPSMV antibodies recognized the virus in an immunoblotting assay. The increase in specific antibodies for CPSMV occurred from the 7th day of the primary response, after immunization. The serial dilution of anti-CPSMV IgY antibodies showed detectable absorbance values ??even at lower antibody concentrations (1:12,800), with the highest absorbances observed at dilutions of 1:100 (0.857) and 1:200 (0.844). Furthermore, the anti-CPSMV IgY antibody was able to recognize CPSMV in metastatic gastric cancer cell line, Pará gastric ascites cell line (AGP01), in the immunofluorescence assay, in which it was possible to observe the internalization of the virus with dispersion in the cytoplasm. Conclusion: These results reinforce the potential of CPSMV to induce an immune response and highlight the IgY platform as a rapid and accurate tool for the production of specific antibodies to Comoviruses.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
